Cerner Provides Access to De-Identified Patient Data for COVID-19 Research
Cerner Corporation is offering select U.S. health systems and academic research centers complimentary access to critical de-identified COVID-19 patient data to help fight the pandemic. The offering will provide eligible health care researchers free access to Cerner’s COVID-19 data set to support epidemiological studies, clinical trials, and medical treatments related to COVID-19. The de-identified patient data secured on Cerner HealtheDataLab, powered by Amazon Web Services Inc. will include COVID-19-related demographics to help track spread and surge, underlying illnesses and chronic conditions, lab results, clinical complications, and more that could help drive medical decisions.
For more information, click here.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
